09/16/2026
New Phase 3 research is adding to the growing conversation around innovative treatments for generalized anxiety disorder (GAD).
Definium Therapeutics recently shared positive results from PANORAMA, a Phase 3 study evaluating DT120, an investigational LSD-based treatment for GAD. The study found that participants receiving the 100 µg dose experienced greater improvements in anxiety symptoms compared with placebo.
This research is especially meaningful to Kadima, as we participated as a clinical trial site in Voyage, the sister Phase 3 study, with Dr. David Feifel serving as an investigator.
We’re proud to contribute to research exploring new possibilities in mental health care and look forward to following what comes next.
DT120 is investigational and has not been approved by the FDA.
Source: Definium Therapeutics, PANORAMA Phase 3 topline results (2026).